PubMed Health⌕ Search

Biomedical subjects

I Mahé

Publications and source records attributed to I Mahé.

At least 19 recordsLinked to original sources
PubMed2002

D-dimer: a characteristic of the coagulation state of each patient with chronic atrial fibrillation.

BACKGROUND AND OBJECTIVE: It is accepted that patients with atrial fibrillation (AF) are characterised by increased levels of plasmatic D-dimers, with a wide inter-individual variability depending on the patients and therapeutic characteristics, but it has not been established if this level was predictive of the risk of arterial thromboembolic event. In order to answer such a question, it has to be established if the D-dimer level in a given patient is characteristic of such a patient (stable over time) if also fluctuating with time (and useless to characterise the patient). METHODS AND RESULTS: One hundred thirty clinically stable patients with chronic AF were recruited (anticoagulant: group 1, antiaggregant aspirin: group 2, no antithrombotic: group 3). During the follow-up of patients without clinical events (n=63), it is notable that in patients with D-dimer levels <500 ng/ml, these remained <1000 ng/ml, in patients with levels between 500 and 1000 ng/ml, these did not reach 1590 ng/ml, and in those with D-dimers >1000 ng/ml, the levels remained relatively stable. Mean age and D-dimer levels were lower in group 1 (74.4 years and 509.1 ng/ml, respectively) than in group 2 (82.4 years, p=0.0003 and 1015.7 ng/ml, p<0.0001, respectively) and in group 3 (79.3 years and 1289.3 ng/ml, p<0.0001, respectively). The effect of the antithrombotic therapy was independent of the age of patients (p=0.017). CONCLUSION: D-dimer levels in patients with chronic AF remain in the same range over time. They are lower on anticoagulant therapy than on antiaggregant or no antithrombotic therapy, irrespective of age. Thus, D-dimers appear to be a useful parameter for assessing the degree of hypercoagulability of patients whatever their age.

Age Factors↗
PubMed2001

[Fatal fulminant acute amebic colitis in metropolitan France].

BACKGROUND: Emergency care is required for patients presenting dysentery and fever. CASE REPORT: A 65-year old patient living in metropolitan France was hospitalized for watery diarrhea that had progressively worsened over the last month. Rectal bleeding was also noted. Serology tests at admission, together with parasitology examination of the fecal matter and colonoscopy led to the diagnosis of intestinal amebiasis a few hours before the patient's rapid death. Serology was positive for amebas and the diagnosis was confirmed by pathology examination of the colonoscopy biopsies. DISCUSSION: The diagnosis of amebiasis should be entertained even in Europe when there is no history of travel to endemic areas in patients who develop suggestive manifestations. Identification of amebas in the fecal matter and serology tests provide certain diagnosis. Clinicians should recall that rapidly fatal outcome is not uncommon in severe forms. Emergency care is mandatory.

Aged↗
PubMed2001

Interaction between aspirin and ACE inhibitors in patients with heart failure.

Both aspirin (acetylsalicylic acid) and ACE inhibitors are often used concomitantly, especially in patients with both heart failure and ischaemic heart disease, which is the most common underlying cause of heart failure. The safety of the association has been questioned because both drugs affect a related prostaglandin-mediated pathway. Thanks to their vasodilating properties, prostaglandins play an important role in heart failure where peripheral vasoconstriction occurs. Some of the beneficial effects of ACE inhibitors might be related to reduced degradation of bradykinin that enhances the synthesis of prostaglandins, while aspirin, through inhibiting the enzyme cyclo-oxygenase, inhibits the production of prostaglandins. To date no prospective study has been conducted to investigate the effect of long term aspirin treatment in the postinfarction period allowing the possible impact of the interaction between aspirin and ACE inhibitors upon survival to be confirmed or negated. However, the practitioner needs to know how to optimise the treatment of his or her patients. In order to stimulate arguments for and against the use of aspirin in patients with heart failure receiving ACE inhibitors, we searched MEDLINE from 1960 to 2000 using the key words heart failure, aspirin, and ACE inhibitors for English language articles and conducted a review of the available data. We report on the potential mechanisms of the interaction and the results of experimental studies on haemodynamic parameters. Results of retrospective clinical studies, subgroup analysis that were undertaken to evaluate the overall action upon haemodynamic parameters and survival of the association are summarised. Conflicting conclusions have been reported in the literature. Many explanations can be advanced to try to understand these conflicting conclusions: differences in study design (results of retrospective trials have to be interpreted with caution); differences in the choice of the evaluation parameter (problem of the clinical relevance of haemodynamic parameters); differences in the characteristics of the patient (different underlying cardiopathy, e.g. heart failure, hypertension or ischaemic cardiopathy); and differences in the type and the dosage of each treatment (especially ACE inhibitors and aspirin since an interaction might occur more often with dosage of aspirin greater than 250mg).

Angiotensin-Converting Enzyme Inhibitors↗
PubMed2000

[Médenox study].

Explore the source record for details and available documents.

Anticoagulants↗
PubMed2000

[Multifactorial cardiovascular risk].

IMPORTANCE OF RISK ASSESSMENT: The prevention of cardiovascular disease is a major public health goal. Cardiovascular diseases are the number one cause of mortality in industrialized countries and account for an important part of health care expenditures. In this context, assessment of the cardiovascular risk for a given subject based on epidemiological data and individual risk factors can be used to determine his/her risk of ischemic heart disease or stroke. THE FRAMINGHAM FORMULA: The most widely used assessment method is the Framingham formula which integrates age, sex, blood pressure, smoking habits and presence or not of diabetes. This formula gives an objective, reproducible estimation of the cardiovascular risk and is a useful tool for therapeutic rationale and primary and secondary prevention. INTEREST AND LIMITATIONS: This new global approach to the individual patient has interesting practical and economic implications but remains imperfect due to certain limitations (other risk factors not taken into account because they are difficult to quantify or occurred recently). For daily practice however, it provides a useful tool appreciated by clinicians and patients.

Cardiovascular Diseases↗
PubMed1998

[Ventricular tachycardia revealing viral myocarditis].

BACKGROUND: The first diagnostic hypothesis in a middle-aged patient presenting with inaugural ventricular tachycardia would be coronary artery disease. If the work-up lacks arguments for this etiology, other cardiac conditions may be involved (dilated cardiopathy, hypertrophic cardiopathy, valve disease arrhythmogenic dysplasia, long QT...). CASE REPORT: A 52-year-old male patient was referred for inaugural ventricular tachycardia. The initial work-up including echocardiography, coronography and the electrophysiologic study provided no explanation. The ventricular tachycardia was later attributed to viral myocarditis. DISCUSSION: Viral myocarditis should always be entertained in patients with unexplained ventricular tachycardia, particular if a viral context is present. In such cases, antibody-labeled scintigraphy is the choice exploration. This noninvasive technique provides determining diagnostic information and helps orient patient management.

Adrenergic beta-Antagonists↗